As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of BioCryst Pharmaceuticals, Inc. The largest reported stake is Deerfield Mgmt, L.P.'s, at 6.81%. 9 filings are on record since September 19, 2025 (Schedule 13G/A, February 12, 2026).
Sell to companies like BioCryst Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 15,827,186 · Sole dispositive: 0 · Shared dispositive: 15,827,186 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 14,586,276 · Sole dispositive: 0 · Shared dispositive: 15,191,098 · SCHEDULE 13G, 2026-08-07
- · Holder: State Street Corporation · Percent: 4.9% · SCHEDULE 13G
- · Reporting person: Vanguard Capital Management · Sole voting: 1,825,410 · Shared voting: 0 · Sole dispositive: 12,961,172 · Shared dispositive: 0 · SCHEDULE 13G, 2026-04-29
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
BioCryst Pharmaceuticals, Inc. has 9 Schedule 13D or 13G filings on record since 2025-09-19. 4 holders' latest filing reports 5% or more of common stock, $0.01 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 2 filings or notices, latest 2026-08-04 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Deerfield Mgmt, L.P. | 6.81% | 14,341,000 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| RA Capital Management, L.P. | 6.2% | 15,827,186 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| State Street Corporation | 6% | 15,191,098 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Vanguard Capital Management | 5.16% | 12,961,172 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind BioCryst Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on BioCryst Pharmaceuticals, Inc. and the records around it.
BioCryst Pharmaceuticals, Inc. elsewhere on the record
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch BioCryst Pharmaceuticals, Inc.
Get an email when BioCryst Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioCryst Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BioCryst Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioCryst Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 15,827,186 | 0 | 15,827,186 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 15,827,186 | 0 | 15,827,186 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 15,827,186 | 0 | 15,827,186 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 15,827,186 | 0 | 15,827,186 | SCHEDULE 13G/A, 2026-08-14 |
| State Street Corporation | 0 | 14,586,276 | 0 | 15,191,098 | SCHEDULE 13G, 2026-08-07 |
| Vanguard Capital Management | 1,825,410 | 0 | 12,961,172 | 0 | SCHEDULE 13G, 2026-04-29 |
The latest filing identifies BioCryst Pharmaceuticals, Inc. by CUSIP 09058V103 and gives its principal executive office as 4505 Emperor Blvd., Suite 200, Durham, NC 27703 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of June 30, 2026 and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-19 | Deerfield Mgmt, L.P. | 5.8% | SCHEDULE 13G |
| 2025-11-12 | RA Capital Management, L.P. | 7.3% | SCHEDULE 13G |
| 2026-02-09 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-02-12 | Deerfield Mgmt, L.P. | 6.81% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.16% | SCHEDULE 13G |
| 2026-05-12 | State Street Corporation | 4.9% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 6% | SCHEDULE 13G |
| 2026-08-14 | RA Capital Management, L.P. | 6.2% | SCHEDULE 13G/A |
Questions about who owns BioCryst Pharmaceuticals, Inc.
Who owns BioCryst Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of BioCryst Pharmaceuticals, Inc.: Deerfield Mgmt, L.P. (6.81%, Schedule 13G/A, filed 2026-02-12), RA Capital Management, L.P. (6.2%, Schedule 13G/A, filed 2026-08-14), State Street Corporation (6%, Schedule 13G, filed 2026-08-07) and Vanguard Capital Management (5.16%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of BioCryst Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of BioCryst Pharmaceuticals, Inc. on this page are Deerfield Mgmt, L.P. (6.81%), RA Capital Management, L.P. (6.2%) and State Street Corporation (6%).
When did Deerfield Mgmt, L.P. buy into BioCryst Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Deerfield Mgmt, L.P. on this page is the Schedule 13G, filed 2025-09-19, reporting 5.8%; its latest, Schedule 13G/A filed 2026-02-12, reports 6.81%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for BioCryst Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.